Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. In order to improve outcomes, there is a critical need for improved tools for detection, accurate staging and resectability assessment. This could improve patient stratification for the most optimal primary treatment modality. Molecular imaging, used in combination with tumor-specific imaging agents, can improve established imaging methods for PDAC. These novel, tumor-specific imaging agents developed to target specific biomarkers have the potential to specifically differentiate between malignant and benign diseases, such as pancreatitis. When these agents are coupled to various types of labels, this type of molecular imaging can provide integrated diagnostic, non-invasive imaging of PDAC as well as image-guided pancreatic surgery. This review provides a detailed overview of the current clinical imaging applications, upcoming molecular imaging strategies for PDAC, and potential targets for imaging, with an emphasis on intraoperative imaging applications.

胰腺导管腺癌（PDAC）预后不良。为了改善治疗效果，迫切需要改进检测工具、准确分期以及可切除性评估方法。这可以优化对患者进行分层，以确定最适合的主要治疗方式。分子成像与肿瘤特异性显像剂联合使用，可以改进已有的胰腺导管腺癌成像方法。这些针对特定生物标志物开发的新型肿瘤特异性显像剂有可能特异性地区分恶性疾病和良性疾病，比如胰腺炎。当这些显像剂与各种类型的标记物结合时，这种分子成像能够为胰腺导管腺癌提供综合诊断、非侵入性成像以及影像引导下的胰腺手术。这篇综述详细概述了当前临床成像应用、即将出现的胰腺导管腺癌分子成像策略以及潜在的成像靶点，重点是术中成像应用。